{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:44:51Z","timestamp":1793810691693,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ahj.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T09:20:03Z","timestamp":1642324803000},"page":"152-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial) \u2013 A phase III study"],"prefix":"10.1016","volume":"246","author":[{"given":"Dirk","family":"von Lewinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-2047","authenticated-orcid":false,"given":"Norbert J","family":"Tripolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-9594","authenticated-orcid":false,"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N","family":"Pferschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5330-904X","authenticated-orcid":false,"given":"Abderrahim","family":"Oulhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Alber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3066-8947","authenticated-orcid":false,"given":"Marianne","family":"Gwechenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-8488","authenticated-orcid":false,"given":"Martin","family":"Martinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deddo","family":"Moertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"N\u00fcrnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Xaver","family":"Roithinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Steinwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"St\u00fchlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-3297","authenticated-orcid":false,"given":"Andreas","family":"Zirlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Benedikt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-8068","authenticated-orcid":false,"given":"Ewald","family":"Kolesnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-4373","authenticated-orcid":false,"given":"Martin","family":"Manninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.01.008_bib0001","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0002","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0003","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0006","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0007","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.01.008_bib0008","first-page":"3599","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"42","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.008_bib0009","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/dom.13299","article-title":"Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study","volume":"20","author":"Kosiborod","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2022.01.008_bib0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.metabol.2009.10.025","article-title":"Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients","volume":"59","author":"von Lewinski","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2022.01.008_bib0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurjhf\/hfp191","article-title":"Functional effects of glucose transporters in human ventricular myocardium","volume":"12","author":"von Lewinski","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2022.01.008_bib0012","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.18632\/aging.102175","article-title":"The anti-inflammatory effects of SGLT inhibitors","volume":"11","author":"Garc\u00eda-Ropero","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ahj.2022.01.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107811","article-title":"The role of sodium glucose co-transporter inhibitors in heart failure prevention","volume":"35","author":"Garla","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ahj.2022.01.008_bib0014","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic to Transl Sci"},{"key":"10.1016\/j.ahj.2022.01.008_bib0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2022.01.008_bib0016","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Hear Rhythm"},{"key":"10.1016\/j.ahj.2022.01.008_bib0017","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","article-title":"Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the spe","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.01.008_bib0018","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2022.01.008_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ahj.2022.01.008_bib0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ahj.2022.01.008_bib0021","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2022.01.008_bib0022","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/sim.5947","article-title":"Sample size calculation for comparing two negative binomial rates","volume":"33","author":"Zhu","year":"2014","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.ahj.2022.01.008_bib0023","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.3390\/ijms22115937","article-title":"Implications of SGLT inhibition on redox signalling in atrial fibrillation","volume":"22","author":"Bode","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ahj.2022.01.008_bib0024","first-page":"503","article-title":"Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction?","volume":"79","author":"von Lewinski","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.ahj.2022.01.008_bib0025","first-page":"626","article-title":"Effects of SGLT2 inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization","volume":"36","author":"Duran","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.ahj.2022.01.008_bib0026","first-page":"323","article-title":"SGLT-2 inhibitors beneficial effects on ventricular repolarization may be protective against atrial fibrillation occurrence","volume":"37","author":"Patoulias","year":"2021","journal-title":"Acta Cardiol Sin"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:08:21Z","timestamp":1757570901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":26,"alternative-id":["S0002870322000072"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.01.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial) \u2013 A phase III study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}